<DOC>
	<DOCNO>NCT01358201</DOCNO>
	<brief_summary>The biological characteristic adult LAL , karyotypic phenotypic particular , fundamentally different Acute Lymphoblastic Leukemia ( ALL ) child , consequently , result treatment substantially low . Additionally , elderly patient tolerate drug consider relatively low-key management LAL suffer toxicity . Although LAL much common patient 60 year age young adult , old adult ALL clearly underrepresented prospective control study . A good portion elderly patient able tolerate intensity standard treatment apply child young adult significant portion receive palliative supportive treatment . The data literature relate specifically elderly population scarce obtain stratification age study design young people ( CALGB , GMALL , PETHEMA ) . To date , group 's recommendation treat PETHEMA LAL-96RI protocol elderly patient protocol less aggressive use high-risk ALL . However , development inhibitor tyrosine kinase LAL effective Bcr / abl positive , relatively common type LAL old patient , require differentiated treat patient . Moreover , analysis data patient treat far LAL-96RI protocol show mediocre result even LAL Bcr / abl negative . This analysis also show significant benefit survival related reduction treatment ( removal L-asparaginase induction cyclophosphamide end induction ) attribute reduction toxicity</brief_summary>
	<brief_title>PETHEMA LAL-07FRAIL : All Treatment In Fragile Patients Ph ' Negative Over 55 Years</brief_title>
	<detailed_description>Prephase ( day -5 -1 ) Dexamethasone 10 mg/m2 bolus day EV 5 day ( -5 -1 ) . Supplementary treatment : hydration minimum 2000 ml / day . allopurinol 300 mg / day . gastric protection ( center ) . daily monitor blood glucose daily monitor renal function . Intrathecal treatment ( diagnosis prophylactic / therapeutic ) day -5 : 12 mg administer intrathecal methotrexate . The morphological study CSF define initial CNS involvement LAL . Although recommended immunophenotypic study CSF , definition CNS involvement LAL ( therapeutic consequence ) base morphological observation blast CSF cytocentrifuge . Remission induction : Tolerance prephase period use establish final indication treatment ( standard protocol frail patient ) . Day 0 free treatment consider +1 first day induction . Systemic treatment - Vincristine ( VCR ) 1 mg ( absolute dose ) EV 1 , 8 , 15 22 . - Dexamethasone ( DEX ) : 10 mg/m2 EV , IM PO day 1-2 , 8-9 day 15-16 , 22-23 . Intrathecal chemotherapy Triple therapy administer methotrexate ( MTX ) , cytosine arabinoside ( ARA-C ) hydrocortisone , day 1 , 8 , 15 22 ( five dos total prophylactic prephase induction ) : MTX 12 mg ARA-C 40 mg Dexamethasone 4 mg If initial infiltration CNS administer every 72 hour disappearance blast cell morphology CSF ( cytocentrifugation ) least two consecutive tap . Alternatively administer liposomal cytarabine ( DepoCyt ) fortnightly authorize center context clinical trial Maintenance treatment first year : Maintenance first year start full recovery induction complete reassessment disease ( include myelogram ) last one year time documentation complete remission . The basic treatment include mercaptopurine 50 mg/m2 PO day methotrexate 20 mg/m2 IM weekly . Once every 3 month added maintenance treatment `` mini-reinduction '' consist - VCR : 1 mg ( absolute dose ) , i.v. , day 1 . - Dexamethasone 40 mg / day , i.v . p.o. , day 1-2 . - Not consider dose triple intrathecal therapy . Reinduction practice first year remission , total 4 quarterly . Maintenance second year : After first year maintenance perform complete reassessment disease ( include myelogram ) patient remain complete remission maintenance continue ( without reinduction ) two year time diagnosis . The initial dose mercaptopurine methotrexate identical first year . Must comply ( increase decrease 20 % dose ) maintain number neutrophil count 1.5 3x109/l platelet 100x109 / L</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Adults 55 year diagnose acute lymphoblastic leukemia Ph 'negative previously treat frailty ( &gt; 3 point Charlson comorbidity index ) LAL 1 . L3 type mature B phenotype ( sIg + ) cytogenetic abnormality characteristic Burkitt LAL ( [ 8 , 14 ] , [ 2 , 8 ] , [ 8 , 22 ] ) . 2 . biphenotypic acute leukemias bilinear 3 . acute undifferentiated leukemia 4 . Patients Charlson comorbidity index less equal 3 ( therefore could potentially benefit intensive treatment PETHEMA LAL07OLD ) . 5 . General condition affect ( grade 3 4 WHO scale ) , attributable LAL . 6 . LAL Ph 'positive ( though still must register LAL07OPH specific protocol ) . 7 . Lack consent patient use clinical data</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
</DOC>